Zimmer Biomet Holdings Surges to 405th in Trading Volume with $235 Million in Shares Exchanged

On June 25, 2025, Zimmer Biomet Holdings, Inc. (ZBH) saw a significant increase in trading volume, with a total of $235 million in shares exchanged, marking a 40.87% rise from the previous day. This surge placed ZBH at the 405th position in terms of trading volume for the day. The stock has been on a steady upward trajectory, rising 0.49% and maintaining a 5-day winning streak, with a cumulative gain of 2.86% over the past five days.

Zimmer Biomet Holdings, Inc. is currently trading at compelling valuation levels, approaching the lowest in recent history. This presents a potential opportunity for investors, as the stock is trading at a lower P/E ratio compared to its large-cap MedTech peers, despite having a higher multi-year top-line CAGR. The company's valuation appears attractive, and the anticipated easing of comparisons in the second half of 2025, along with the integration of Paragon 28 and new product launches, are expected to drive top-line growth.

BTIG analyst Ryan Zimmerman has maintained a Buy rating on Zimmer Biomet Holdings, setting a price target of $117.00. Zimmerman's rating is based on a combination of factors, including the company's historically low valuation levels and its leadership position in the U.S. knee and hip segments. Despite recent market share losses in these areas, Zimmer Biomet is actively addressing these challenges by introducing new products to fill gaps in their portfolio. Additionally, the stock is at a level that has historically acted as support, suggesting a potential for stabilization and upward movement.